Enter the vial size and the bacteriostatic water you added to get the concentration and the syringe units for a quantity on a U-100 syringe. Survodutide is investigational and no regulator has approved a dose for it; the only figures with a source are the doses studied in its trials, and this page converts them without recommending any of them. The compound itself is covered in the survodutide guide.
A 10 mg vial of survodutide reconstituted with 2 mL of bacteriostatic water gives a concentration of 5.0 mg/mL, or 50 mcg per unit on a U-100 syringe. For a 0.6 mg weekly dose, draw the syringe to 12.0 units (0.12 mL). At that dose the vial provides about 16.67 doses.
Defaults: 10 mg is the most common labelled vial among the survodutide tests on file, 21 Sep 2026 (25 of 40); 2 mL was chosen for simple arithmetic; 0.6 mg weekly is the lowest dose studied in Phase 2 — a trial dose, used here for arithmetic only, not a recommendation.
Draw the syringe up to
That's one 600 mcg dose. Add 2 mL of water to your 10 mg vial first.
Survodutide has 40 independent lab tests on file at Peptigrity, averaging 99.61% HPLC purity across the tests that report one. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the Survodutide lab-test records.
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma: a 29-amino-acid backbone structurally modified from glucagon, acylated with a C18 fatty diacid. Its half-life of approximately 7 days is what enables once-weekly subcutaneous dosing. It is in Phase 3 for obesity (the SYNCHRONIZE programme) and for MASH, and is sold as a research-use-only compound by third-party laboratories.
The table sets out what the compound page states (page last updated August 2026, read 21 September 2026), and at what level of evidence.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | A dual GLP-1/glucagon receptor agonist (BI 456906), Boehringer Ingelheim and Zealand Pharma | Investigational; Phase 3 |
| Route and frequency? | Once-weekly subcutaneous dosing, enabled by a half-life of approximately 7 days | Human RCT |
| Doses studied? | Phase 2: 0.6 mg through 4.8 mg weekly, under clinical supervision. Phase 3 SYNCHRONIZE-1: 3.6 mg and 6.0 mg | Human RCT (Phase 2 and Phase 3 published) |
| An approved dose? | None — not approved by the FDA, EMA or any other regulator as of August 2026 | None |
| A Peptigrity dose? | “Does Peptigrity recommend a survodutide dose? No.” | None — declined |
Peptigrity does not recommend a survodutide dose; these are the doses studied in Phase 2 (0.6 mg through 4.8 mg weekly), administered under clinical supervision, and survodutide is not approved for human consumption. The table is dated to the compound page (last updated August 2026) and converts each dose at the page default of 5 mg/mL.
| Dose studied in Phase 2 | Frequency and route | What the compound page reports | Draw at 5 mg/mL (10 mg + 2 mL) |
|---|---|---|---|
| 0.6 mg | Weekly, subcutaneous | The lowest dose studied in Phase 2 | 12 units (0.12 mL) |
| 4.8 mg | Weekly, subcutaneous | The highest dose studied in Phase 2: 14.9% average weight loss over 46 weeks on the planned-treatment analysis, versus 2.8% with placebo (n=387); participants who reached and maintained 4.8 mg lost up to 18.7% | 96 units (0.96 mL) |
| Doses in between | Weekly | The compound page gives the range's ends only and does not list the arms between them | — not printed |
The two figures for 4.8 mg are different analyses, not a range: 14.9% is the planned-treatment result across the 4.8 mg arm; 18.7% is the upper figure for the participants who reached and kept that dose. A 10 mg vial holds about 16.7 quantities of 0.6 mg and about 2.1 of 4.8 mg.
Peptigrity does not recommend a survodutide dose; these are the doses studied in the Phase 3 SYNCHRONIZE-1 trial (n=725, 76 weeks; New England Journal of Medicine, June 2026), as the compound page reports them.
| Dose studied in Phase 3 | Primary result (treatment-regimen estimand) | Efficacy estimand (participants adhering to treatment) | Draw at 5 mg/mL (10 mg + 2 mL) |
|---|---|---|---|
| 3.6 mg | 12.2% average weight loss, versus 5.4% with placebo | 15.3%, versus 3.2% with placebo | 72 units (0.72 mL) |
| 6.0 mg | 13.0% average weight loss, versus 5.4% with placebo | 16.6%, versus 3.2% with placebo | 120 units — more than a 1 mL barrel; 60 units at 10 mg/mL |
The primary figures are 12.2% and 13.0%; the efficacy-estimand figures are a different analysis of the same trial, not a higher reading of it. The compound page also reports that 28.5% of the 6.0 mg group lost at least 20% of body weight, versus 6.6% on placebo.
The table converts reference quantities to syringe units at the default of 5.0 mg/mL (10 mg of Survodutide in 2 mL), and counts how many draws of each a vial holds. Every row is arithmetic, not a dose: read the units for the amount you already intend to measure.
| Quantity | Draw at 5.0 mg/mL | Volume | Draws from a 5 mg vial | Draws from a 10 mg vial |
|---|---|---|---|---|
| 600 mcg | 12.0 units | 0.12 mL | 8.33 | 16.67 |
| 1 mg | 20.0 units | 0.20 mL | 5 | 10 |
| 2 mg | 40.0 units | 0.40 mL | 2.5 | 5 |
| 3.6 mg | 72.0 units | 0.72 mL | 1.39 | 2.78 |
| 4.8 mg | 96.0 units | 0.96 mL | 1.04 | 2.08 |
The same Survodutide quantity lands on a different mark depending on how much water went into the vial. Read down the column for the concentration you actually mixed; a units figure carried across from another column is simply wrong.
| Quantity | At 10 mg/mL (10 mg + 1 mL) | At 5.0 mg/mL (10 mg + 2 mL) | At 2.5 mg/mL (10 mg + 4 mL) |
|---|---|---|---|
| 600 mcg | 6.0 units | 12.0 units | 24.0 units |
| 1 mg | 10.0 units | 20.0 units | 40.0 units |
| 2 mg | 20.0 units | 40.0 units | 80.0 units |
| 3.6 mg | 36.0 units | 72.0 units | — over a 1 mL barrel (144 units) |
| 4.8 mg | 48.0 units | 96.0 units | — over a 1 mL barrel (192 units) |
Every cell is the same arithmetic: units = (quantity in mg ÷ concentration in mg/mL) × 100 on a U-100 syringe. More water spreads the same mass over more units, which is the fix when a small quantity would otherwise sit at two or three units, where a one-unit misread is a large error.
Each Survodutide vial holds as many draws as its labelled mass divided by the quantity per draw; the water volume changes nothing about it. The grid counts draws, not weeks — survodutide was dosed once weekly in the Phase 2 trials, per the compound page; that is a trial design, not a recommendation.
| Vial size | At 600 mcg | At 1 mg | At 2 mg | At 3.6 mg | At 4.8 mg |
|---|---|---|---|---|---|
| 5 mg | 8.33 | 5 | 2.5 | 1.39 | 1.04 |
| 10 mg | 16.67 | 10 | 5 | 2.78 | 2.08 |
The labelled mass is not a guarantee of the mass in your vial: net content is a separate measurement from purity, and certificates on file often measure a few percent above or below the label.
No label exists for survodutide and no page on Peptigrity sets a diluent volume for it, so the volume is a choice. At the page default of 5 mg/mL (a 10 mg vial with 2 mL), every Phase 2 dose from 0.6 mg to 4.8 mg fits one 1 mL U-100 barrel, at 12 to 96 units; with 1 mL the 0.6 mg dose drops to 6 units, where a one-unit misread is a large error. The technique is covered once, elsewhere, as general guidance rather than a survodutide-specific finding: reconstituting peptides step by step and the bacteriostatic water guide.
Survodutide is not approved by the FDA, EMA or any other regulator as of August 2026, and no regulatory submission has been announced. SYNCHRONIZE-1 (obesity) is published, SYNCHRONIZE-2 (obesity with type 2 diabetes) is due for presentation at the EASD annual meeting, and SYNCHRONIZE-CVOT results are expected later in 2026. In MASH it holds FDA Breakthrough Therapy designation (granted October 2024 for non-cirrhotic MASH with moderate or advanced fibrosis) and is in two Phase 3 trials, LIVERAGE and LIVERAGE-Cirrhosis. It is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption.
Identity is the practical check: some vendors label survodutide as a generic “GLP-1/glucagon dual agonist” without naming BI 456906, and mazdutide is a different molecule with the same mechanism. The dual- versus triple-agonist comparison is in retatrutide vs survodutide vs mazdutide, and the receptor pharmacology in the survodutide science guide.
Independent test records: survodutide lab tests. Tracked prices, last read 21 September 2026: a median of $9.80 per mg across 12 comparable offers, ranging from $2.75 to $15.00 per mg, in vials from 5 mg to 10 mg — see survodutide price per milligram. The category page is weight loss & metabolic.
It depends on the concentration. At the page default of 5 mg/mL (a 10 mg vial with 2 mL of water), 0.6 mg is 12 units (0.12 mL) on a U-100 syringe. With 1 mL in the same vial (10 mg/mL) it is 6 units; with 4 mL (2.5 mg/mL) it is 24 units. A units figure quoted without a concentration cannot be used.
There isn't one. Survodutide is not approved by any regulator and Peptigrity does not recommend a dose. The doses studied in Phase 2 were 0.6 mg through 4.8 mg weekly, administered under clinical supervision, and the Phase 3 SYNCHRONIZE-1 trial studied 3.6 mg and 6.0 mg. Those are trial doses, not recommendations.
In the Phase 2 obesity trial (n=387), 14.9% on average at 4.8 mg over 46 weeks on the planned-treatment analysis, versus 2.8% with placebo; participants who reached and maintained 4.8 mg lost up to 18.7%. In Phase 3 SYNCHRONIZE-1 (n=725, 76 weeks), 12.2% at 3.6 mg and 13.0% at 6.0 mg versus 5.4% with placebo on the primary estimand, and 15.3% and 16.6% versus 3.2% on the efficacy estimand.
At 5 mg/mL (a 10 mg vial with 2 mL) 4.8 mg is 96 units (0.96 mL), which fits a 1 mL U-100 barrel. The Phase 3 amount of 6.0 mg would be 120 units at that concentration, more than one barrel; at 10 mg/mL (the same vial with 1 mL) it is 60 units.
No. Both are dual GLP-1/glucagon receptor agonists, but they are different molecules from different sponsors: survodutide (BI 456906) from Boehringer Ingelheim, mazdutide (IBI362) from Innovent Biologics. Mazdutide was approved in China in June 2025; survodutide is not approved anywhere.